Patients must have histologically or cytologically confirmed papillary histology renal cell carcinoma which is metastatic or locally advanced disease not amenable to surgical resection; (NOTE: a designation of type I or type II should be made by the local pathologist if possible); mixed histologies containing type I or type II will be allowed provided that they contain >= % of the papillary component
Patients must have tissue available and be willing to submit for independent pathologic review in order to classify type I versus type II papillary disease
Type  or  diabetes requiring anti-hyperglycemic medication (e.g. metformin, glipizide, insulin)
Patients with Diabetes Type I or uncontrolled Type II as judged by the Investigator
Wild-type TP status
Prior history of anaphylaxis with this product type
Type I or type II diabetes, or Hgb Ac > .%
EXCLUSION - INFUSION: Uncontrolled autoimmune disease needing systemic steroids or steroid sparing agents except for hypothyroidism or type I diabetes
Participant has a concurrent diagnosis of type I or type II diabetes that is being treated with insulin or an oral antidiabetic agent; (participants whose type II diabetes is controlled with diet and/or exercise alone are eligible provided they meet all other eligibility criteria)
Part B: Must have a type of malignancy that is being studied.
Patients may have neurofibromatosis type  or 
Subjects with neurofibromatosis type  (NF) are also eligible
There is no limitation of amount or the type of prior therapy or drugs
Has a confirmed diagnosis of type  diabetes or type  diabetes that has been diagnosed by an HbAc ? ., or is on any hypoglycemic medications (insulin, metformin, etc)
FOR ALL PHASES (Ib AND II): Type I diabetes or patients on insulin therapy are not allowed; uncontrolled type II diabetes not allowed (glycosylated hemoglobin [HbAc] > .)
History of autoimmune disease except for controlled, treated thyroidism or Type  diabetes
Tumor type:
Pathologically confirmed MPNST, with or without underlying diagnosis of neurofibromatosis type  (diagnostic criteria for neurofibromatosis type )
Pedunculated polyps (as defined by Paris Classification type Ip or Isp)
Patients with gliomatosis cerebri type  or 
Patients with autoimmune hypothyroid disease or type I diabetes on replacement treatment are eligible
Patients with uncontrolled type  or type  diabetes; patients with an elevated risk of hyperglycemia should be excluded from study
Patients must not have type I or II diabetes that requires anti-hyperglycemic medication
Special cases of high-risk lymphoma, including but not limited to: plasma dendritic cell type, hepato-splenic T cell type, gamma delta panniculitic T cell type, muco-cutaneous natural killer (NK) cell type, and stage III-IV nasal NK cell type\r\n* Primary treatment failure\r\n* Relapse after autologous SCT\r\n* Non-CR after salvage regimen\r\n*In first CR or any later CR
Type  diabetes or uncontrolled Type  diabetes
Patients with uncontrolled Diabetes Type I or Type II
Histologically or cytologically confirmed recurrent or metastatic SCCHN\r\n* All primary sites are eligible excluding World Health Organization (WHO) type III or EpsteinBarr virus (EBV) nasopharyngeal (WHO type I and WHO type II allowed as long as they are EBV negative)
Epithelial type
Patients with type II diabetes currently already on metformin
Patients with diabetes type I or uncontrolled type II (HbAc >  % assessed locally) as judged by the investigator
Participants with fasting blood glucose values that are > institutional ULN; in addition, patients with type  diabetes will also be excluded; however, patients with type  diabetes will be allowed if diagnosed >=  months prior to enrollment, and if presenting with regular hemoglobin AC (HbAC) =< % at screening
Subjects with Type II diabetes are only allowed if their HbAC is less than  percent at study entry.
History of Type  or Type  diabetes requiring regular medication
Patients who have had prior therapy with chemokine receptor type  (CXCR) inhibitors
Patients must not have active or history of clinically significant autoimmune disorders/conditions including type I diabetes; type II diabetes, vitiligo, stable hypothyroidism, and thyroid disease well controlled with thyroid replacement will not be considered exclusion criteria
Patients must not have active or history of clinically significant autoimmune disease, defined as requiring systemic therapy, such as type I diabetes; type II diabetes, vitiligo, stable hypothyroidism, and thyroid disease well controlled with thyroid replacement will not be considered exclusion criteria
Patients undergoing either a Type II or III radical hysterectomy (Piver Classification)
Second degree AV block Type  (Mobitz Type / Wenckebach type)
Patients with abnormal fasting glucose values (>  mg/dl) at screening will be excluded; in addition, patients with type  diabetes will also be excluded; however, patients with type  diabetes will be allowed if diagnosed >=  months prior to enrollment, and if presenting with regular hemoglobin AC (HbAC) =< % at screening
Type  diabetes or uncontrolled Type  diabetes
Part A: Any type of solid tumor (\all comer\)
History of autoimmune disease except controlled, treated hypothyroidism or type I diabetes
Type  or  diabetes requiring antihyperglycemic medication
Confirmed diagnosis of refractory celiac disease Type  (RCD-II)
Patients with Diabetes Type I or uncontrolled Type II (HbAc >  mmol/mol assessed locally) as judged by the Investigator
Fracture is closed, Gustilo Type I or II.
Type  or Type  diabetes
Type I Diabetes
Patients with any type of brain tumor will be eligible for participation
Type I diabetes
Type II diabetes requiring chronic therapy with insulin
Type  or  diabetes requiring anti-hyperglycemic medication
Type I diabetes or uncontrolled type II diabetes
Type  or type  diabetes
Type  diabetes
Use of type III antiarrhythmics (e.g. amiodarone)
Group : Patients known to be KIT wild type.
No limitations exist for type or amount of prior therapy
type  diabetes
Fitzpatrick skin type I-VI
Reported current diagnosis or history of type I diabetes or type  diabetes.
Individuals with Fitzpatrick skin type I are ineligible
Individuals with Fitzpatrick skin type V or VI are ineligible
Patients with Fitzpatricks scale skin type IV-VI
Any type of ostomy
Any disease type
Group III: Participants with well-controlled vascular risk factors, such as treated hypertension, treated hyperlipidemia or well-controlled type II diabetes (glucose levels < ) may be included
Have a diagnosis of any type of NHL and =<  years from the last treatment
Patients with diabetes type  or uncontrolled type II (HbAc > % assessed locally)
